Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Saved in:
| Title: | Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. |
|---|---|
| Authors: | Rodler E; Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Sharma P; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA. Electronic address: psharma2@kumc.edu., Barlow WE; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gralow JR; Department of Breast Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA., Puhalla SL; Division of Hematology/Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA., Anders CK; Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Goldstein L; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brown-Glaberman UA; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA; New Mexico MU-NCORP, Albuquerque, NM, USA., Huynh TT; Department of Hematology/Oncology, Kaiser Permanente NCORP, Anaheim, CA, USA; Kaiser Permanente Medical Group, Anaheim, CA, USA., Szyarto CS; Department of Hematology/Oncology, Genesee Hematology Oncology PC, Flint, MI, USA; Michigan CRC NCORP, Flint, MI, USA., Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Pathak HB; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Swisher EM; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA., Radke MR; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA., Timms KM; Department of Research, Myriad Genetics, Salt Lake City, UT, USA., Lew DL; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Miao J; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Pusztai L; Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Hayes DF; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2023 Feb; Vol. 24 (2), pp. 162-174. Date of Electronic Publication: 2023 Jan 06. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36623515 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rodler+E%22">Rodler E</searchLink>; Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sharma+P%22">Sharma P</searchLink>; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA. Electronic address: psharma2@kumc.edu.<br /><searchLink fieldCode="AU" term="%22Barlow+WE%22">Barlow WE</searchLink>; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Gralow+JR%22">Gralow JR</searchLink>; Department of Breast Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Puhalla+SL%22">Puhalla SL</searchLink>; Division of Hematology/Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Anders+CK%22">Anders CK</searchLink>; Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Goldstein+L%22">Goldstein L</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tripathy+D%22">Tripathy D</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Brown-Glaberman+UA%22">Brown-Glaberman UA</searchLink>; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA; New Mexico MU-NCORP, Albuquerque, NM, USA.<br /><searchLink fieldCode="AU" term="%22Huynh+TT%22">Huynh TT</searchLink>; Department of Hematology/Oncology, Kaiser Permanente NCORP, Anaheim, CA, USA; Kaiser Permanente Medical Group, Anaheim, CA, USA.<br /><searchLink fieldCode="AU" term="%22Szyarto+CS%22">Szyarto CS</searchLink>; Department of Hematology/Oncology, Genesee Hematology Oncology PC, Flint, MI, USA; Michigan CRC NCORP, Flint, MI, USA.<br /><searchLink fieldCode="AU" term="%22Godwin+AK%22">Godwin AK</searchLink>; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Pathak+HB%22">Pathak HB</searchLink>; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Swisher+EM%22">Swisher EM</searchLink>; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Radke+MR%22">Radke MR</searchLink>; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Timms+KM%22">Timms KM</searchLink>; Department of Research, Myriad Genetics, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Lew+DL%22">Lew DL</searchLink>; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Miao+J%22">Miao J</searchLink>; Department of Biostatistics, SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Pusztai+L%22">Pusztai L</searchLink>; Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Hayes+DF%22">Hayes DF</searchLink>; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Hortobagyi+GN%22">Hortobagyi GN</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2023 Feb; Vol. 24 (2), pp. 162-174. <i>Date of Electronic Publication: </i>2023 Jan 06. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36623515 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(22)00739-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 162 Titles: – TitleFull: Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rodler E – PersonEntity: Name: NameFull: Sharma P – PersonEntity: Name: NameFull: Barlow WE – PersonEntity: Name: NameFull: Gralow JR – PersonEntity: Name: NameFull: Puhalla SL – PersonEntity: Name: NameFull: Anders CK – PersonEntity: Name: NameFull: Goldstein L – PersonEntity: Name: NameFull: Tripathy D – PersonEntity: Name: NameFull: Brown-Glaberman UA – PersonEntity: Name: NameFull: Huynh TT – PersonEntity: Name: NameFull: Szyarto CS – PersonEntity: Name: NameFull: Godwin AK – PersonEntity: Name: NameFull: Pathak HB – PersonEntity: Name: NameFull: Swisher EM – PersonEntity: Name: NameFull: Radke MR – PersonEntity: Name: NameFull: Timms KM – PersonEntity: Name: NameFull: Lew DL – PersonEntity: Name: NameFull: Miao J – PersonEntity: Name: NameFull: Pusztai L – PersonEntity: Name: NameFull: Hayes DF – PersonEntity: Name: NameFull: Hortobagyi GN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2023 Feb Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 24 – Type: issue Value: 2 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |
